Bryostatin 1 Plus Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer or Stomach Cancer
NCT00005599 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2013-06-21
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 and paclitaxel in treating patients who have locally advanced or metastatic esophageal cancer or stomach cancer.
Conditions
- Esophageal Cancer
- Gastric Cancer
Interventions
- DRUG
-
bryostatin 1
- DRUG
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
Memorial Sloan Kettering Cancer Center
lead OTHER
Principal Investigators
-
Gary K. Schwartz, MD · Memorial Sloan Kettering Cancer Center
Study Design
- Purpose
- TREATMENT
- Masking
- NONE
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2000-02-29
- Completion
- 2004-08-31
Countries
- United States
Study Locations
More Related Trials
-
Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia
NCT01159301 ·Status: TERMINATED ·Phase: PHASE1
-
Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma
NCT00005625 ·Status: COMPLETED ·Phase: PHASE2
-
Dolastatin 10 in Treating Patients With Advanced Kidney Cancer
NCT00003914 ·Status: COMPLETED ·Phase: PHASE2
-
Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors
NCT00112476 ·Status: COMPLETED ·Phase: PHASE1
-
Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder
NCT00085410 ·Status: TERMINATED ·Phase: PHASE2
-
2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors
NCT00030095 ·Status: COMPLETED ·Phase: PHASE1
-
Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma
NCT00003802 ·Status: COMPLETED ·Phase: PHASE2
-
Pyroxamide in Treating Patients With Advanced Cancer
NCT00042900 ·Status: COMPLETED ·Phase: PHASE1
-
Enzastaurin and Bevacizumab in Treating Patients With Locally Advanced or Metastatic Cancer
NCT00550927 ·Status: COMPLETED ·Phase: PHASE1
-
Endostatin in Treating Patients With Advanced Refractory Solid Tumors
NCT00004872 ·Status: COMPLETED ·Phase: PHASE1
-
Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction
NCT00061958 ·Status: TERMINATED ·Phase: PHASE2
-
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
NCT00245102 ·Status: COMPLETED ·Phase: PHASE2
-
Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors
NCT00004922 ·Status: COMPLETED ·Phase: PHASE2
-
KRN5500 in Treating Patients With Metastatic Solid Tumors
NCT00002923 ·Status: COMPLETED ·Phase: PHASE1
-
Talabostat in Treating Patients With Metastatic Kidney Cancer
NCT00489710 ·Status: WITHDRAWN ·Phase: PHASE2
-
S9926 Temozolomide in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors
NCT00005597 ·Status: COMPLETED ·Phase: PHASE2
-
PS-341 in Treating Patients With Hematologic Cancer
NCT00006098 ·Status: COMPLETED ·Phase: PHASE1
-
Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer
NCT00095693 ·Status: TERMINATED ·Phase: PHASE2
-
Sorafenib in Treating Patients With Advanced Malignant Solid Tumors
NCT00810394 ·Status: COMPLETED ·Phase: PHASE2
-
Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma
NCT00003008 ·Status: COMPLETED ·Phase: PHASE2
-
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment
NCT04557956 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck Cancer
NCT00281866 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors.
NCT01248858 ·Status: TERMINATED ·Phase: PHASE1
-
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
NCT00104871 ·Status: COMPLETED ·Phase: PHASE2
-
S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas
NCT00217620 ·Status: COMPLETED ·Phase: PHASE2